You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    AbstractProject Summary Cognition Therapeutics IncsCogrxmission is to develop effective therapeutics for Alzheimer s diseaseADOligomers of the brain protein Amyloid betaA Oshave been identified as toxic components that are involved with disease progressionCognition has identified a subset of sigmareceptor binding modulators that displaces A Os from synaptic receptor sites and clears them into the ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a protein drug for pancreatic cancer treatment

    SBC: ProDa BioTech L.L.C.            Topic: NCI

    Abstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: NCI

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Dual View Endoscopy for Colonoscopy

    SBC: Omniscient Imaging, Inc.            Topic: 102

    AbstractAn estimatedmillion colonoscopies are performed annually in the US at a cost of about $Bhowever current colonoscopes with forward vision fail to detectof precancerous polypsOverof the missed polyps are located on or behind numerous folds in the colon where they are hidden from the sight of a forward view colonoscopeIn this research proposalwe propose to complete our development of an imagi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitisCMit creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treatThere are now an estimatedUS cases andcases of CM worldwide annuallywith estimated mortality ofper yearCM is caused when Cryptococcus neoformansa basidiomycete fungal pathogeninvades the central nervous systemCNSIt ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Automated Object Contouring Methods & Software for Radiotherapy Planning

    SBC: Quantitative Radiology Solutions LLC            Topic: 101

    Abstract Innew cancer cases are estimated to occur in the USwhere nearly two thirds will have radiation therapyRTGiven that there are overRT centers in the USand current systems for contouring organs at riskOARsrely mostly on manual methodsthere is a strong commercial opportunity for producing a software system that can contour OARs in medical images at a high degree of automation and for impactin ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government